Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Trevi Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.51, Trevi Therapeutics, Inc. trades at 7.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -24.8%, return on invested capital of -23.1% and a free cash flow yield of -3.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 38.86. Over the past 52 weeks the share price ranged from $9.82 to $20.22, with a beta of 0.98.
Trevi Therapeutics, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 1 Strong Buy and 17 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Trevi Therapeutics, Inc. (TRVI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.9% / 30% · Interest income / Revenue 301800000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.9% / 33% · Receivables / Mkt Cap (36m) 0.08% / 49% · Interest income / Revenue 301800000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.9% / 33.33% · Receivables / Mkt Cap (24m) 0.08% / 33.33% · Interest income / Revenue 301800000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.04% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.4% / 33.33% · Receivables / Avg Assets (4Q) 0.43% / 33.33% · Interest income / Revenue 301800000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.3% / 33.33% · (Cash+Recv) / Total Assets 96.9% / 33.33% · Interest income / Revenue 301800000.0% / 5% | Fail |
No. As of September 2026, Trevi Therapeutics, Inc. (TRVI) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Trevi Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 301800000.0% of each dividend: Trevi Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.